vitamin D3 capsule for Parkinson's (NCT07096336)
Vitamin D normalizes brain waves
- Trial ID
- NCT07096336
- Official Title
- Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
- Goal
- Vitamin D normalizes brain waves
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Bangladesh Medical University
- Study Type
- INTERVENTIONAL
- Enrollment
- 15 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- vitamin D3 capsule
Summary For Families
The goal is to see whether correcting low vitamin D can change abnormal brain wave patterns in men with Parkinson's, which could reflect altered neuronal excitability and brain function. Participants will take an oral vitamin D3 capsule to raise serum 25(OH)D; vitamin D3 acts on neurons and calcium signaling and may reduce neuronal hyperexcitability, and researchers will measure quantitative EEG while patients stay on their usual levodopa because vitamin D3 is not expected to change how levodopa works. The study seeks men aged 51 to 70 with Parkinson's up to Hoehn and Yahr stage 3, BMI 18.5 to 24.9, confirmed hypovitaminosis D (<30 ng/ml), who are on levodopa and not already taking vitamin D or other medications or having medical conditions that affect EEG or calcium metabolism, and active smokers are excluded.
Locations
- Bangladesh medical university, Dhaka, Shahbag, Bangladesh
Frequently Asked Questions
- What is this trial testing?
- This trial is studying vitamin D3 capsule. The goal is to see whether correcting low vitamin D can change abnormal brain wave patterns in men with Parkinson's, which could reflect altered neuronal excitability and brain function. Participants will take an oral vitamin D3 capsule to raise serum 25(OH)D; vitamin D3 acts on neurons and calcium signaling and may reduce neuronal hyperexcitability, and researchers will measure quantitative EEG while patients stay on their usual levodopa because vitamin D3 is not expected to change how levodopa works. The study seeks men aged 51 to 70 with Parkinson's up to Hoehn and Yahr stage 3, BMI 18.5 to 24.9, confirmed hypovitaminosis D (<30 ng/ml), who are on levodopa and not already taking vitamin D or other medications or having medical conditions that affect EEG or calcium metabolism, and active smokers are excluded.
- Who can participate?
- Participants must be between 51 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 4 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- A baseline visit (Session A1) and a follow-up visit after 8 weeks (Session AD); the intervention period is 8 weeks.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Brain wave recording (EEG) (non-invasive). Confirm the full schedule with the study coordinator.